Cargando…

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

PURPOSE: This study aimed to determine whether baseline blood inflammatory markers can predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). METHODS: The study included 158 patients with mRCC treated with first-line targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sung Han, Park, Eun Young, Joo, Jungnam, Chung, Jinsoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312581/ https://www.ncbi.nlm.nih.gov/pubmed/30662462 http://dx.doi.org/10.1155/2018/1953571

Ejemplares similares

Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis
por: Keiner, Cathrine, et al.
Publicado: (2022)

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
por: Janisch, Florian, et al.
Publicado: (2021)

Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray
por: Kim, Sung Han, et al.
Publicado: (2020)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis
por: Kim, Sung Han, et al.
Publicado: (2019)

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
por: Santoni, M, et al.
Publicado: (2013)

Potential Clinical Value of Pretreatment De Ritis Ratio as a Prognostic Biomarker for Renal Cell Carcinoma
por: Li, Jinze, et al.
Publicado: (2021)

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma
por: AKTEPE1, Oktay Halit, et al.
Publicado: (2021)

Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy
por: Kim, Sung Han, et al.
Publicado: (2019)

Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy
por: Kim, Sung Han, et al.
Publicado: (2017)

Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy
por: Ha, Heon, et al.
Publicado: (2019)

Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis
por: Byun, Seok-Soo, et al.
Publicado: (2016)

De-Ritis Ratio Is Associated with Mortality after Cardiac Arrest
por: Lu, Zhengri, et al.
Publicado: (2020)

Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma
por: Kim, Hyeon-Jong, et al.
Publicado: (2022)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
por: Lalani, Aly-Khan A., et al.
Publicado: (2018)

Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Neutrophil–lymphocyte ratios in the prognostication of primary non-metastatic nasopharyngeal carcinoma()
por: Liew, Kong Yew, et al.
Publicado: (2017)

The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
por: Kim, Sung Han, et al.
Publicado: (2016)

Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma
por: Kim, Tae Woo, et al.
Publicado: (2019)

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
por: Chrom, Pawel, et al.
Publicado: (2018)

A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy
por: Kim, Sung Han, et al.
Publicado: (2017)

The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma
por: Canat, Lütfi, et al.
Publicado: (2018)

Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Clinical Significance of Preoperative Neutrophil – to - Lymphocyte Ratio in Renal Cell Carcinoma
por: Otunctemur, Alper, et al.
Publicado: (2016)

Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression
por: Arda, Ersan, et al.
Publicado: (2018)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer
por: Ribnikar, Domen, et al.
Publicado: (2020)

Pretreatment Aspartate Aminotransferase-to-Alanine Aminotransferase (De Ritis) Ratio Predicts the Prognosis of Nonmetastatic Nasopharyngeal Carcinoma
por: Wu, Jiayuan, et al.
Publicado: (2019)

Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
por: Baum, Yoram S., et al.
Publicado: (2016)

Neutrophil-Lymphocyte Ratio in Small Renal Masses
por: Bazzi, Wassim M., et al.
Publicado: (2014)

Neutrophil lymphocyte ratio in aute renal failure
por: Erdem, E.
Publicado: (2015)

A High De Ritis Ratio is Associated with Mortality in Adult Trauma Patients
por: Tsai, Ching-Hua, et al.
Publicado: (2023)

Letter to the editor: Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma
por: Joob, Beuy, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio may be predict of mortality in all conditions
por: Balta, S, et al.
Publicado: (2013)

The neutrophil-to-lymphocyte ratio may indicate when to start hemodialysis
por: Lee, Tae Won, et al.
Publicado: (2022)

High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated With Sarcopenia Risk in Hospitalized Renal Cell Carcinoma Patients
por: Hu, Qiang, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer
por: Kim, Hyunho, et al.
Publicado: (2018)

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio May Contribute Little Compared to Standard Preoperative Evaluation
por: Kalil, Renato Abdala Karam, et al.
Publicado: (2018)

The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer
por: Knittelfelder, Olivia, et al.
Publicado: (2020)

The Elevated De Ritis Ratio on Admission Is Independently Associated with Mortality in COVID-19 Patients
por: Drácz, Bálint, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eqs7so4d10rqnkqtnhfgk475fl